MiNK Therapeutics stock falls after William Blair downgrade
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
H.C. Wainwright Downgrades MiNK Therapeutics (INKT) to Neutral
July 15, 2025 10:33 AM EDTH.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics (NASDAQ: INKT) from Buy to Neutral.
The analyst comments "Dual-function of iNKT cells to treating solid tumors published in Frontiers in Immunology. This morning, MiNK Therapeutics announced that a publication discussing the mechanism of action (MoA) of CAR-iNKT cells was published in Frontiers in Immunology (see publication here). The publication was authored by leading experts in iNKT cell biology and discusses the use of iNKT cells as an off-the-shelf platform for treating solid tumors. CAR-iNKT cell therapy is a next-generation approach which lacks alloreactivity,... More
